Alchemab Therapeutics initiates Phase 1 clinical trial of ATLX-1282 and announces Series A financing extension
Follows successful completion of pre-clinical activities by Alchemab as part of earlier licensing deal with Eli Lilly and Company for ATLX-1282
Financing included participation from Eli Lilly and Company and Ono Venture Investment alongside significant support from world-class existing investors
Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 first-in-human study of ATLX-1282. ATLX-1282 was licensed to Eli Lilly and Company (Lilly) in May 2025 as part of an exclusive global licensing agreement, which included a milestone payment to Alchemab following the initiation of the Phase 1 first-in-human study. Alchemab will conduct the first-in-human study for ATLX-1282 and Lilly will lead further development and commercialisation of the therapy. The Company also announced a $32 million Series A extension financing, bringing the Company’s total Series A investment to date to $114 million. The round included participation from Ono Venture Investment (OVI) alongside a blue-chip syndicate of existing specialist investors which includes RA Capital, SV Health Investors, DCVC Bio and Lightstone Ventures and strategic investment by Lilly.
